trametinib tablets
trametinib tablets,
for oral use Initial U.S. Approval: 2013
As specified in the prescribing information, trametinib tablets is indicated for the treatment of skin cancer, non-small cell lung cancer (NSCLC), thyroid cancer, solid tumors.
Facts about trametinib tablets
Approval Date: 2013
Proprietary Name: MEKINIST (trametinib) tablets
Active Ingredient(s): trametinib
FDA-approved use: skin cancer, non-small cell lung cancer (NSCLC), thyroid cancer, solid tumors.
Dosage Form: Tablets: 0.5 mg, 2 mg
Medicine Approved By: US FDA
Manufacturer: Novartis Pharmaceuticals Corporation
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “trametinib tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For trametinib tablets
Approved accessible "trametinib tablets"
Mekinist (trametinib) tablets were initially approved in 2013 to treat patients with certain melanomas. In 2022, CDER approved Mekinist in combination with Tafinlar [see page 18] to treat patients aged six years and older with specific genetically mutated solid tumors (a gene called BRAF V600E) whose disease has progressed and who have no other treatment options.
MEKINIST is a prescription medicine used: • alone or in combination with a medicine called dabrafenib to treat a type of skin cancer called melanoma. • in combination with dabrafenib, to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery. • in combination with dabrafenib to treat a type of lung cancer called non-small cell lung cancer (NSCLC). • in combination with dabrafenib to treat a type of thyroid cancer called anaplastic thyroid cancer (ATC). • in combination with dabrafenib to treat solid tumors in adults and children 6 years and older. MEKINIST is not for use in treating people with colorectal cancer.
Active ingredient: trametinib Inactive ingredients: Tablet Core: colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate (vegetable source), mannitol, microcrystalline cellulose, sodium lauryl sulfate. Tablet Coating: hypromellose, iron oxide red (2 mg tablets), iron oxide yellow (0.5 mg tablets), polyethylene glycol, polysorbate 80 (2 mg tablets), titanium dioxide.
How can 1 go about obtaining trametinib tablets?
If trametinib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
MEKINIST (trametinib) tablets, for oral use Initial U.S. Approval: 2013
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in